Generic versus brand-name drugs used in cardiovascular diseases

[1]  статья Редакционная,et al.  Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals , 2017 .

[2]  Icmje admin,et al.  International Committee of Medical Journal Editors Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals , 2017 .

[3]  John R. Peters,et al.  High-cost generic drugs--implications for patients and policymakers. , 2015, The New England journal of medicine.

[4]  S. Grajek,et al.  Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb , 2015, Platelets.

[5]  A. Kesselheim,et al.  High-cost generic drugs--implications for patients and policymakers. , 2014, The New England journal of medicine.

[6]  Jinsun Park,et al.  Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate. , 2014, Clinical therapeutics.

[7]  G. Mancia,et al.  Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. , 2014, European journal of internal medicine.

[8]  Qinghui Zhou,et al.  [Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals]. , 2014, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[9]  T. Brennan,et al.  Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes , 2014, Annals of Internal Medicine.

[10]  J. Ioannidis,et al.  Non-publication and delayed publication of randomized trials on vaccines: survey , 2014, BMJ : British Medical Journal.

[11]  Andrea Costantini,et al.  Pharmacokinetic bioequivalence crossover study of branded generic and innovator formulations of the cholesterol lowering agent ezetimibe , 2014, Clinical pharmacology in drug development.

[12]  A. Khuroo,et al.  Pharmacokinetic comparison and bioequivalence evaluation of losartan/ hydrochlorothiazide tablet between Asian Indian and Japanese volunteers. , 2014, International journal of clinical pharmacology and therapeutics.

[13]  Alan D. Lopez,et al.  Measuring the global burden of disease. , 2013, The New England journal of medicine.

[14]  R. Póvoa,et al.  Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM. , 2013, Clinical therapeutics.

[15]  R. Fernandes,et al.  Branded Versus Generic Clopidogrel in Cardiovascular Diseases: A Systematic Review , 2013, Journal of cardiovascular pharmacology.

[16]  C. Lu,et al.  Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. , 2013, Drug research.

[17]  Kate Faasse,et al.  The Effect of an Apparent Change to a Branded or Generic Medication on Drug Effectiveness and Side Effects , 2013, Psychosomatic medicine.

[18]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[19]  Hyo‐Soo Kim,et al.  Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial. , 2013, Clinical therapeutics.

[20]  T. Hong,et al.  Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial. , 2013, Clinical therapeutics.

[21]  S. Srimahachota,et al.  Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography. , 2012, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[22]  M. Togni,et al.  A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial. , 2012, Archives of cardiovascular diseases.

[23]  A. Tselepis,et al.  Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome , 2012, Angiology.

[24]  A. Leś,et al.  Bioequivalence and pharmacokinetics of two 10-mg bisoprolol formulations as film-coated tablets in healthy white volunteers: a randomized, crossover, open-label, 2-period, single-dose, fasting study. , 2012, International journal of clinical pharmacology and therapeutics.

[25]  C. White,et al.  Efficacy and Safety of Innovator versus Generic Drugs in Patients with Epilepsy: A Systematic Review , 2012, Pharmacotherapy.

[26]  H. Krumholz,et al.  Generic atorvastatin and health care costs. , 2012, The New England journal of medicine.

[27]  A. Tselepis,et al.  Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate , 2012, Expert opinion on pharmacotherapy.

[28]  A. Kesselheim,et al.  Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs , 2010, Drugs.

[29]  Jian-jun Zou,et al.  Bioequivalence study of clopidogrel 75 Mg tablets in healthy male volunteers , 2012 .

[30]  P. Bakke,et al.  Effects of lifestyle intervention in persons at risk for type 2 diabetes mellitus - results from a randomised, controlled trial , 2011, BMC public health.

[31]  R. Češka,et al.  Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. , 2011, International angiology : a journal of the International Union of Angiology.

[32]  K. Seung,et al.  Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. , 2011, Clinical therapeutics.

[33]  T. Brennan,et al.  The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money. , 2011, Health affairs.

[34]  A. Tavassoli,et al.  The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: results of the OPCES study , 2011, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[35]  W. Ageno,et al.  Brand Name versus Generic Warfarin: A Systematic Review of the Literature , 2011, Pharmacotherapy.

[36]  L. Manzoli,et al.  Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. , 2011, The American journal of cardiology.

[37]  William H Shrank,et al.  Physician Perceptions About Generic Drugs , 2011, The Annals of pharmacotherapy.

[38]  A. Filipe,et al.  Study on the bioequivalence of two formulations of eplerenone in healthy volunteers under fasting conditions: data from a single-center, randomized, single-dose, open-label, 2-way crossover bioequivalence study. , 2011, Arzneimittel-Forschung.

[39]  Hyo‐Soo Kim,et al.  Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. , 2010, Clinical therapeutics.

[40]  N. Yang,et al.  The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. , 2010, Clinical therapeutics.

[41]  Sungha Park,et al.  Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study. , 2010, Clinical therapeutics.

[42]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[43]  Gang-yi Liu,et al.  Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. , 2010, Clinical therapeutics.

[44]  Gang-yi Liu,et al.  Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: A single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. , 2010, Clinical therapeutics.

[45]  J. Octavio,et al.  Clinical Bioequivalence of a Dose of Clopidogrel Leti Cravid Tablets 75 mg Versus Clopidogrel Sanofi Plavix Tablets 75 mg Administered on a Daily Dose for 7 Days on Healthy Volunteers: A Clinical Trial , 2010, American journal of therapeutics.

[46]  M. Iqbal,et al.  Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. , 2010, Clinical therapeutics.

[47]  G. Keller,et al.  Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. , 2010, Clinical therapeutics.

[48]  A. Filipe,et al.  Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. , 2009, Clinical Therapeutics.

[49]  J. Shen-Tu,et al.  Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects. , 2009, Clinical therapeutics.

[50]  Hyuk-Jae Chang,et al.  Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial. , 2009, Clinical therapeutics.

[51]  M. J. Kim,et al.  Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. , 2009, Clinical therapeutics.

[52]  Gang-yi Liu,et al.  Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers. , 2009, Clinical therapeutics.

[53]  William H Shrank,et al.  Patients' perceptions of generic medications. , 2009, Health affairs.

[54]  M Alan Brookhart,et al.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. , 2008, JAMA.

[55]  M. Mijares,et al.  Eficacia comparativa de dos presentaciones de clopidogrel en la inhibición de la agregación plaquetaria , 2008 .

[56]  Sungha Park,et al.  Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial. , 2008, Clinical therapeutics.

[57]  Y. Ahn,et al.  Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension. , 2007, Clinical therapeutics.

[58]  Thomas A Trikalinos,et al.  The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey , 2007, Canadian Medical Association Journal.

[59]  T. Tzai,et al.  Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. , 2007, Clinical therapeutics.

[60]  R Brian Haynes,et al.  Interventions to enhance medication adherence in chronic medical conditions: a systematic review. , 2007, Archives of internal medicine.

[61]  Joseph Beyene,et al.  Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data , 2007, BMC medical research methodology.

[62]  D. Tomassoni,et al.  Single-Dose, Randomized, Crossover Bioequivalence Study of Amlodipine Maleate versus Amlodipine Besylate in Healthy Volunteers , 2007, Clinical and experimental hypertension.

[63]  F. Vallée,et al.  Bioequivalence study of two different tablet formulations of carvedilol in healthy volunteers. , 2011, Arzneimittel-Forschung.

[64]  A. Fareed,et al.  Competency profile of locally manufactured clopidogrel Lowplat and foreign manufactured clopidogrel Plavix in patients of suspected ischemic heart disease (CLAP-IHD). , 2005, JPMA. The Journal of the Pakistan Medical Association.

[65]  M. Kochen,et al.  What do primary care patients think about generic drugs? , 2005, International journal of clinical pharmacology and therapeutics.

[66]  J. Douketis,et al.  Are Brand-Name and Generic Warfarin Interchangeable? Multiple N-of-1 Randomized, Crossover Trials , 2005, The Annals of pharmacotherapy.

[67]  C. Kan,et al.  Efficacy and tolerability of the switch from a branded to a generic garfarin sodium product: an observer-blinded, randomized, crossover study , 2005 .

[68]  J. Madrigal,et al.  Equivalencia terapéutica de dosis única de tres presentaciones de captopril en hipertensas esenciales , 2005 .

[69]  C. Kan,et al.  Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study. , 2005, Clinical therapeutics.

[70]  E. Shin,et al.  Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects. , 2004, Clinical therapeutics.

[71]  E. Vargas,et al.  Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. , 2004, Current therapeutic research, clinical and experimental.

[72]  A. Grahnén,et al.  Implications of intraindividual variability in bioavailability studies of furosemide , 2004, European Journal of Clinical Pharmacology.

[73]  T. R. K. Rao,et al.  Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. , 2003, Current therapeutic research, clinical and experimental.

[74]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[75]  S. Rezaee,et al.  BIOEQUIVALENCE STUDY OF ATENOLOL: PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION , 2003 .

[76]  J. Pedraz,et al.  In vitro and in vivo Equivalence of Two Oral Atenolol Tablet Formulations , 2002, Arzneimittelforschung.

[77]  V. Wiwanitkit,et al.  A randomized crossover study to evaluate LDL-cholesterol lowering effect of a generic product of simvastatin (Unison Company) compared to simvastatin (Zocor) in hypercholesterolemic subjects. , 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[78]  V. Wiwanitkit,et al.  LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor™) in Thai hypercholesterolemic subjects – a randomized crossover study, the first report from Thailand , 2002, BMC clinical pharmacology.

[79]  S. Chinn.  A simple method for converting an odds ratio to effect size for use in meta-analysis. , 2000, Statistics in medicine.

[80]  D. McGee,et al.  A Randomized, Crossover Comparison of Warfarin Products in the Treatment of Chronic Atrial Fibrillation , 2000, The Annals of pharmacotherapy.

[81]  V. Bongers,et al.  Comparison of the Effect of Two Metoprolol Formulations on Total Ischaemic Burden , 1999 .

[82]  D. Smith,et al.  A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin , 1998 .

[83]  T. Ramesh Kumar,et al.  Bioequivalence Study of Two Slow-Release Diltiazem Formulations Using Dynamic Measures in Healthy Volunteers , 1997 .

[84]  J. Ioannidis,et al.  Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.

[85]  E. Zajac,et al.  Postabsorption Concentration Peaks with Brand‐Name and Generic Verapamil: A Double‐Blind, Crossover Study in Elderly Hypertensive Patients , 1997, Journal of clinical pharmacology.

[86]  M. Murray,et al.  Variable Furosemide Absorption and Poor Predictability of Response in Elderly Patients , 1997, Pharmacotherapy.

[87]  W. Dunlap,et al.  Meta-Analysis of Experiments With Matched Groups or Repeated Measures Designs , 1996 .

[88]  B. Sheridan,et al.  Bioavailability and platelet function effects of acetylsalicylic acid , 1996 .

[89]  H. Chiang,et al.  A comparison of antihypertensive effects between two formulations of atenolol: tenolol and tenormin. , 1995, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.

[90]  S. Waldman,et al.  Effects of Food on the Bioequivalence of Different Verapamil Sustained‐Release Formulations , 1995, Journal of clinical pharmacology.

[91]  M. Adams,et al.  Pharmacodynamic and Pharmacokinetic Comparisons to Evaluate Bioequtvalence of Atenolol , 1995 .

[92]  B. Carter,et al.  Differences in Serum Concentrations of and Responses to Generic Verapamil in the Elderly , 1993, Pharmacotherapy.

[93]  T. Arafat,et al.  A bioequivalence study of two products of furosemide tablets. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[94]  S. Kaojarern,et al.  Bioavailability and pharmacokinetics of furosemide marketed in Thailand. , 1990, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[95]  S. Garg,et al.  Comparative pharmacokinetic and pharmacodynamic study of four different brands of propranolol in normal volunteers. , 1989, International journal of clinical pharmacology, therapy, and toxicology.

[96]  B. Davies,et al.  Effect of two formulations of a beta blocker on fibrinolytic response to maximum exercise. , 1989, Medicine and science in sports and exercise.

[97]  B. Tabatznik,et al.  Comparative efficacy and bioequivalence of a brand-name and a generic triamterene-hydrochlorothiazide combination product. , 1989, Clinical pharmacy.

[98]  G. O. Williams,et al.  Once‐Daily Propranolol for Hypertension: A Comparison of Regular‐Release, Long‐Acting, and Generic Formulations , 1989, Pharmacotherapy.

[99]  B. Sharma,et al.  Comparative bioequivalence study of furosemide in patients with edema of renal origin. , 1987, International journal of clinical pharmacology, therapy, and toxicology.

[100]  J. Green,et al.  Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride. , 1987, Drug intelligence & clinical pharmacy.

[101]  H. Luus,et al.  Comparative bio-availability of four formulations of furosemide. , 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[102]  U. Gupta,et al.  Comparative bioequivalence study of furosemide in human volunteers. , 1984, International journal of clinical pharmacology, therapy, and toxicology.

[103]  R M Ings,et al.  Comparative bioavailability of two furosemide formulations in humans. , 1984, Journal of pharmaceutical sciences.

[104]  Rebecca Y. C. Wang,et al.  Efficacy of two proprietary preparations of frusemide in patients with congestive heart failure , 1984, The Medical journal of Australia.

[105]  F. Juma,et al.  A comparative study of the efficacy of seven brands of frusemide tablets. , 1984, East African medical journal.

[106]  D. Rubin,et al.  Comparing Effect Sizes of Independent Studies , 1982 .